OBJECTIVE: To rapidly evaluate the efficacy

safety and economy of butylphthalide in the treatment of ischemic cerebrovascular disease

so as to provide reference for clinical and policy makers. METHODS: The Chinese and English data and official websites of health technology assessment（HTA） institutions at home and abroad such as CNKI

Wanfang Data

PubMed

Embase and the Cochrane Library were retrieved to collect the HTA report

systematic review/Meta-analysis and pharmacoeconomics study of butylphthalide in the treatment of ischemic cerebrovascular disease. Qualitative description was used to summarize the included studies. RESULTS: A total of 39 articles were enrolled

including 22 systematic reviews/Meta-analysis

15 pharmacoeconomic studies

and 2 articles with Meta-analysis and pharmacoeconomic studies at the same time. Results of pooled analysis showed that butylphthalide

compared with other drugs in improving circulation or as an addition to conventional treatment

could improve the effective rate of ischemic cerebrovascular disease

and improve the National Institutes of Health Stroke Scale score

Barthel index rating scale score

activity of daily living scale score

China Stroke Scale score and the level of examination laboratory indicators. The total incidence of adverse drug reactions in the butylphthalide intervention group was similar to that in the control group

yet there might be a certain risk in the impact on liver function

which should be paid attention to in the clinical application. In terms of drug economy

there is no unified conclusion whether butylphthalide intervention group had better economy than the control group. CONCLUSIONS: Butylphthalide is effective and safe in the treatment of ischemic cerebrovascular disease

yet its economy needs to be further evaluated.